etentamig + carfilzomib + dexamethasone

The combination of **etentamig + carfilzomib + dexamethasone** is an investigational therapy for **multiple myeloma**. **Etentamig** (ABBV-383) is a bispecific antibody targeting **B-cell maturation antigen** (BCMA) and **CD3**, developed to engage T-cells for targeted lysis of multiple myeloma cells. **Carfilzomib** is a second-generation selective, irreversible **proteasome inhibitor** that induces apoptosis in malignant plasma cells. **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and cytotoxic activity, commonly used as an adjunct in myeloma regimens to enhance anti-cancer efficacy and limit immune-mediated toxicities. This triplet combination is under clinical investigation in adults with multiple myeloma to evaluate safety, pharmacokinetics, and efficacy, including in relapsed/refractory settings[1][3][5].